Retinal Degenerations Completed Phase 3 Trials for Brolucizumab (DB14864)

Also known as: Retinal Degeneration / Degeneration retinal

IndicationStatusPhase
DBCOND0041282 (Retinal Degenerations)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03954626Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMDTreatment